In SCCHN, FGFR1 amplification was significantly associated with poor prognostic factors such as higher T stage, lymphovascular invasion, and higher numbers of visceral metastases.[22]Tumor heterogeneity, unstandardized FISH criteria for FGFR1 amplification, varying adjuvant treatment, and small sample size may contribute to the controversial results. Here, FGFR1 is linked to head and neck squamous cell carcinoma.